Gonadorelin

Also known as · GnRH · LHRH · Factrel (animal) · Lutrepulse (withdrawn)

01 / Dosing schedule

Cited dosing

Gonadorelin has no current US-marketed human FDA prescribing information (Factrel is now an animal-drug label; Lutrepulse was discontinued). Historic human labels used single-dose diagnostic testing and continuous-pulse pump infusion. The popular subcutaneous TRT-adjunct schedule is compounding-pharmacy practice, not FDA-approved.

Pulsatile pump — fertility induction in men with hypogonadotropic hypogonadism

PhaseDose & frequency
Pump dose5–20 mcg subQ every 60–120 minutes
DurationContinuous, months (until spermatogenesis)
RouteSubcutaneous via portable infusion pump
Median time to first sperm~6 months

Source · Mao JF et al. Sertoli-Cell and Spermatogenesis Response to GnRH vs hCG/hMG in Men With CHH. JCEM 2017 ↗

Compounding-pharmacy TRT-adjunct schedule (not FDA-approved)

PhaseDose & frequency
Conservative100 mcg subQ 2–3x weekly
Common telehealth default100–200 mcg subQ twice daily
RouteSubcutaneous, abdomen or thigh
EvidenceNo RCT vs hCG; each dose fires a single LH pulse then clears

Source · See TRT-adjunct evidence review (mechanism + trial gap) ↗

Source indication · Historically: diagnostic assessment of gonadotropin reserve; fertility induction via pulsatile pump. Not FDA-approved for TRT adjunct.

Injection frequency
Pulsatile pump: every 60–120 min. Bolus schedules: 2–3x weekly to twice daily.
Injection sites
Abdomen or thigh for subQ boluses. Pump infusion typically subQ.

02 / Reconstitution

Reconstitution reference

Research-grade gonadorelin typically ships as a 10 mg lyophilized vial. A common prep is 10 mg with 10 mL bacteriostatic water = 1 mg/mL (1000 mcg/mL). At that concentration, a 100 mcg dose is 0.1 mL = 10 units on a U‑100 syringe.

Vial10 mg
BAC water10 mL
Concentration1 mg/mL
Example dose100 mcg
On a U‑100 syringe10 units on U‑100
Open the reconstitution calculator →

03 / Overview

Protocol overview

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH, LHRH). It stimulates the anterior pituitary to release LH and FSH, which in turn drive gonadal steroid and gamete production.

Historic FDA-approved human indications used gonadorelin as a diagnostic agent and via portable pulsatile pump for fertility induction. Both human products (Factrel injection, Lutrepulse) have been withdrawn or reclassified.

The 2–4 minute plasma half-life is the central mechanistic issue for TRT-adjunct use. A single subcutaneous bolus fires one LH pulse, then clears — unlike hCG, which supplies continuous LH-receptor activity for days.

No randomized controlled trial compares twice-daily subcutaneous gonadorelin to hCG on TRT for testicular volume, intratesticular testosterone, or sperm-count endpoints. The popular telehealth schedule sits between two published literatures it does not formally belong to.

04 / References

References

  1. Coviello AD et al. Low-Dose Human Chorionic Gonadotropin Maintains Intratesticular Testosterone in Normal Men. JCEM 2005 (comparator for TRT-adjunct goal) ↗
  2. Mao JF et al. Effects of pulsatile GnRH pump vs hCG/hMG in men with congenital hypogonadotropic hypogonadism. JCEM 2017 ↗